I can certainly agree with you there, but I have a feeling that they look at K as their potential legacy. I think they stick it out until it is a successfully used and widespread cancer treatment. Which, in the grand scheme of things, is probably only another 10 years away. 5 more years for trials and approval then 5 for market share capture (and hopefully market dominance ). I but they are willing to give it another 10 years before bowing out.